|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
FGFR1 translocation with concurrent myeloproliferative neoplasm, systemic mastocytosis, and lymphoblastic lymphoma: a case report.
|
29107667 |
2018 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.
|
28551329 |
2017 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
BCR-FGFR1, CNTRL-FGFR1, CUX1-FGFR1, FGFR1OP-FGFR1, MYO18A-FGFR1 and ZMYM2-FGFR1 fusions in myeloproliferative neoplasms are non-receptor-type FGFR kinases, whereas FGFR1-TACC1, FGFR2-AFF3, FGFR2-BICC1, FGFR2-PPHLN1, FGFR3-BAIAP2L1 and FGFR3-TACC3 fusions in solid tumors are transmembrane-type FGFRs with C-terminal alterations.
|
27245147 |
2016 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Taking its high specificity for FGFRs into account, infigratinib could be beneficial for EMS patients and should be further investigated for the treatment of myeloproliferative neoplasms with FGFR1 abnormalities.
|
26391436 |
2016 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Here we describe another case of myeloproliferative neoplasm with chromosome translocation t(8;19) involving FGFR1 gene associated with systemic mastocytosis.
|
24551307 |
2014 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Fine-needle aspiration cytology of T-lymphoblastic lymphoma associated FGFR1 rearrangement myeloproliferative neoplasm.
|
23904402 |
2014 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We report herein a rare case of a t(1;8)(q25;p11.2) with a TPR-FGFR1 rearrangement, in which the patient presented with myeloproliferative neoplasm-like symptoms and T-lymphoblastic lymphoma.
|
25037443 |
2014 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
CTD_human |
The 8p11 myeloproliferative syndrome is a rare, aggressive myeloproliferative neoplasm characterized by constitutively active FGFR1 fusion proteins that arise from specific chromosomal translocations and which drive aberrant proliferation.
|
22875613 |
2013 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Localization of the FOP-FGFR1 fusion kinase to centriolar satellites may be relevant to myeloproliferative neoplasm disease progression.
|
23554904 |
2013 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Hematologic malignancies associated with FGFR1 abnormalities present in heterogeneous forms, including myeloproliferative neoplasm, acute myeloid leukemia (AML), T- or B-lineage lymphoblastic leukemia/lymphoma, and even mixed phenotype acute leukemia.
|
23609419 |
2013 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
A ZMYM2-FGFR1 8p11 myeloproliferative neoplasm with a novel nonsense RUNX1 mutation and tumor lysis upon imatinib treatment.
|
23751892 |
2013 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Here, we report a new translocation at the FGFR1 locus in a patient who carried t(1;8)(q25;p11.2) and presented with myeloproliferative neoplasm-like symptoms.
|
22619110 |
2012 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.
|
21527531 |
2011 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
CTD_human |
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
|
21936542 |
2011 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
The introduction of JAK2 mutation testing has changed dramatically the diagnostic algorithms for myeloproliferative neoplasms (MPNs) but there is still a place for conventional cytogenetic analysis in the initial work-up of MPN cases, particularly as this group of myeloid disorders has been expanded to include chronic eosinophilic leukaemia and myeloid neoplasms with abnormalities of the PDGFRA, PDGFRB, and FGFR1 genes.
|
21431636 |
2011 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The KG-1a cell line is developed from a human stem cell myeloproliferative neoplasm as the result of intragenic disruption and a chromosomal translocation of the FGFR1 gene and the FGFR1OP2 gene encoding a protein of unknown function called FOP2 (FGFR1 Oncogene Partner 2).
|
21745565 |
2011 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Important changes include (1) the change of nomenclature of myeloproliferative disorder to myeloproliferative neoplasm emphasizing the clonal nature of these disorders; (2) the classification of mast cell disease as an MPN; (3) the reorganization of the eosinophilic disorders into a molecularly defined category of PDGFRA, PDGFRB and FGFR1-associated myeloid and lymphoid neoplasms with eosinophilia and chronic eosinophilic leukemia, not otherwise specified; and (4) refinement of the diagnostic criteria for PV, ET and PMF incorporating recently described molecular markers, JAK2V617F, JAK2 exon 12 mutations and MPL mutations.
|
20191332 |
2010 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Three of the four FGFR1-rearranged cases were associated with myeloproliferative neoplasms but none, including the two with sole 8p11.2, displayed the typical phenotype for stem cell leukemia/lymphoma (SCLL) and only one had eosinophilia; the fourth case had AML-M4.
|
20143402 |
2010 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Protein tyrosine kinase abnormalities, including translocations or mutations involving ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB, and FGFR1, have been used as the basis for classifying myeloproliferative neoplasms (MPN).
|
20626469 |
2010 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature.
|
18096225 |
2008 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Rearrangements of the genes encoding the fibroblast growth factor receptor 1 (FGFR1) and platelet-derived growth factor receptors (PDGFR) alpha or beta receptor tyrosine kinases are found in a rare but important subset of patients with atypical myeloproliferative disorders that are usually but not always associated with eosinophilia.
|
18566537 |
2008 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder.
|
17321332 |
2007 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We describe a case of coexisting BCR-ABL negative myeloproliferative disorder and precursor T-cell lymphoblastic lymphoma associated with t(8;13) involving FGFR1 at 8p11 in a 14-year-old boy who presented with generalized lymphadenopathy and an abdominal mass.
|
16777224 |
2007 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
The 8p11 myeloproliferative syndrome (EMS) is an aggressive, atypical stem cell myeloproliferative disorder associated with chromosome translocations that disrupt and constitutively activate FGFR1 by fusion to diverse partner genes.
|
17698633 |
2007 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.
|
16410451 |
2006 |